Intra-individual Comparison of Conventional and Digital PET/CT Scanners

Isala225 enrolled

Overview

In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of mescellaneous cancers.

There will be a single injection of the PET radiopharmaceutical FDG, followed by a conventional PET/CT scan and a digital PET scan, in this order or vice versa.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

225

Conditions

Breast Cancer Lung Cancer Esophageal Cancer Miscellaneous Neoplasm

Interventions

Digital PET/CT scanDIAGNOSTIC_TEST

The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria In order to be eligible to participate in this study, a subject must meet all of the following criteria: * referred to Isala for a clinically indicated FDG-PET/CT scan * suspected or proven lung cancer, esophageal cancer, breast cancer or miscellaneous cancer, either as a primary diagnosis or follow-up study * signed informed consent Exclusion criteria A potential subject who meets any of the following criteria will be excluded from participation in this study: * age \< 18 years * incapacitated adults * prisoners * pregnant patients * unable to undergo two consecutive PET/CT scans

Locations (1)

Isala

Zwolle, Overijssel, Netherlands

Outcomes

Primary Outcomes

Diagnostic outcome of the PET/CT study

Time frame: approximately 2 hours

Secondary Outcomes

PET image quality

Time frame: approximately 2 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.